Jens Wendland

1 presentation

• W111. A FIRST-IN-HUMAN STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF KYN-5356, A FIRST-IN-CLASS INHIBITOR OF KYNURENINE AMINOTRANSFERASE II (KAT-II)

  2026 ASCP Annual Meeting